Three-in-One Stop Computed Topography Angiography(CTA) and CT Perfusion(CTP) in Cerebrovascular Disease
Launched by XIN LOU · Mar 21, 2025
Trial Information
Current as of April 29, 2025
Not yet recruiting
Keywords
ClinConnect Summary
This clinical trial is looking at a new type of imaging test for patients with cerebrovascular diseases, which are conditions that affect the blood vessels in the brain. The study aims to create a "one-stop" CT examination that combines three different imaging techniques into one visit. This will help doctors better understand issues like blockages or narrowing of blood vessels, brain aneurysms, and other related diseases. The goal is to improve diagnosis and treatment for patients experiencing strokes or other brain-related issues.
To participate in this trial, you need to be between 18 and 100 years old and have certain conditions like artery blockages or brain aneurysms. However, there are some people who won't be eligible, such as those with severe kidney or liver problems, or those who are pregnant. If you qualify and decide to join the study, you would undergo the CT scans and provide some clinical information about your health. It’s important to note that participation is voluntary, and you will be asked to sign consent forms to ensure you understand the process. This trial is not yet recruiting participants, but it aims to help improve care for patients with cerebrovascular diseases in the future.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Age≥18 \<100years
- • Head and neck artery stenosis/occlusion, moyamoya disease, aneurysm, artery dissection, etc., may include patients with acute stroke, chronic cerebral ischemia, and asymptomatic patients. After clinical assessment, CT perfusion imaging is required
- • The image quality meets the requirements of diagnosis and post-processing
- • Patients who follow the scanning strategy to complete the examination
- • The patient or his or her family agrees to provide clinical data and follow-up
- • Patients or their families sign informed consent forms
- Exclusion Criteria:
- • \< 18 years old
- • People who are allergic to iodine contrast agents, or who cannot be tested temporarily due to taking metformin or aminoglycoside drugs
- • Renal failure patient
- • Severe cardiac insufficiency
- • Severe liver damage
- • Patients with an expected survival of less than 1 year
- • Patients with cerebrovascular diseasePregnant woman
About Xin Lou
Xin Lou is a dedicated clinical trial sponsor committed to advancing medical research and innovation. With a strong emphasis on ethical practices and patient safety, Xin Lou collaborates with leading healthcare professionals and institutions to conduct rigorous clinical studies across various therapeutic areas. The organization is focused on developing novel treatments and improving patient outcomes by leveraging cutting-edge technologies and methodologies. Xin Lou's commitment to transparency and collaboration ensures that its trials contribute valuable insights to the medical community and enhance the overall quality of healthcare.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Beijing, , China
Patients applied
Trial Officials
Xin Lou
Study Chair
Chinese PLA General Hospital
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported